Sera Prognostics | GenomeWeb

Sera Prognostics

According to one physician familiar with the test, it is a much needed diagnostic tool, but without insurance coverage it is too expensive for wide use.

Published this week in AJOG, the study found that the test could predict delivery before 37 weeks with 75 percent sensitivity and 74 percent specificity.

The mass spec-based proteomic test identified women who gave birth at or before 35 weeks gestation with an area under the receiver operating curve of .93.

This fall the company is rolling out a limited commercial launch of the MRM mass spectrometry-based proteomic test, with a broader launch to come next year.

With the additional funding, Sera aims to develop new tests for predicting the risk of preterm birth in women in developing countries, the company said.

The firm is validating the test and expects results to be available in the second quarter of 2015 with commercial launch of the test following around mid-year.

The funding follows a $19.3 million Series A round Sera closed in 2011 and will support development of its proteomic test for assessing women's risk of preterm delivery.

Sera Prognostics said this week that Lee Hood will serve as a scientific advisor to the company.

Sera Prognostics said this week that it has completed enrollment of 5,500 women in its Proteomic Assessment of Preterm Risk clinical study supporting the validation of its PreTRM proteomic test for predicting risk of preterm birth.

Protein biomarker firm Applied Proteomics has decided to use multiple-reaction mass spectrometry as the platform for its clinical proteomic tests, John Blume, the company's chief science officer, told ProteoMonitor this week.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.